Wire · opportunities
Korean drugmaker Yuhan wins trial approval for kidney disease candidate
◆ Sectors
Biotech
◆ Geography
South Korea
◆ Source
◆ Verified
Fusion42 · 16 November 2026 · Fusion42 review
South Korea's Ministry of Food and Drug Safety approved a Phase 1 trial for Yuhan's YH34180, a small-molecule oral drug candidate aimed at treating chronic kidney disease by targeting inflammation and fibrosis pathways.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clearer window to enter the Korean chronic kidney disease drug market as local regulator greenlights first-in-human trials for novel compounds targeting unmet needs in inflammation and fibrosis.
◆ Coverage
1 source · 16 Nov 2026
◆ Related on Wire
◆ Topics
Biotechclinical-trialkidney-diseasedrug-developmentsouth-koreabiotech